Difference between revisions of "Team:EPFL"
| Line 30: | Line 30: | ||
</div> | </div> | ||
<div class="col-sm-3"> | <div class="col-sm-3"> | ||
| − | <a href="#"> | + | <a href="https://2018.igem.org/Team:EPFL/Description#Vaccine"> |
<img src="https://static.igem.org/mediawiki/2018/9/93/T--EPFL--vaccine.png" class="img-circle project_part" alt="Vaccine" width="255" height="255"> <br> | <img src="https://static.igem.org/mediawiki/2018/9/93/T--EPFL--vaccine.png" class="img-circle project_part" alt="Vaccine" width="255" height="255"> <br> | ||
</a> | </a> | ||
| Line 36: | Line 36: | ||
</div> | </div> | ||
<div class="col-sm-3"> | <div class="col-sm-3"> | ||
| − | <a href="#"> | + | <a href="https://2018.igem.org/Team:EPFL/Description#Dendritic"> |
<img src="https://static.igem.org/mediawiki/2018/1/1f/T--EPFL--Dendritic.png" class="img-circle project_part" alt="Dendritic" width="255" height="255"> <br> | <img src="https://static.igem.org/mediawiki/2018/1/1f/T--EPFL--Dendritic.png" class="img-circle project_part" alt="Dendritic" width="255" height="255"> <br> | ||
</a> | </a> | ||
| Line 42: | Line 42: | ||
</div> | </div> | ||
<div class="col-sm-3"> | <div class="col-sm-3"> | ||
| − | <a href="#"> | + | <a href="https://2018.igem.org/Team:EPFL/Description#Followup"> |
<img src="https://static.igem.org/mediawiki/2018/3/3c/T--EPFL--follow_up.png" class="img-circle project_part" alt="follow_up" width="255" height="255"> <br> | <img src="https://static.igem.org/mediawiki/2018/3/3c/T--EPFL--follow_up.png" class="img-circle project_part" alt="follow_up" width="255" height="255"> <br> | ||
</a> | </a> | ||
Revision as of 18:26, 1 August 2018
CAPOEIRA
Cancer Personalized Encapsulin Immunotherapy and Relapse Assay
What is CAPOEIRA ?
While cancer is still the disease of the 21st century, new insights and approaches are changing the landscape of cancer therapy. Cancer immunotherapy is becoming a key technique for the successful fight against cancer. The goal of cancer immunotherapy is to harness the immune system in the fight against cancer. The project that the EPFL 2018 iGEM team is presenting is focused on the development of a new therapeutic approach to target specific types of cancer using immunotherapy methods, with a focus on vaccines. Furthermore, the project aims to integrate the personalized medicine approaches, by using patient-specific neoantigens to trigger the immune system and produce the response against cancer. The project is exhaustive and can be divided into the following parts:
Detection of cancer patient specific tumor mutations and neoantigens
Expression of the neoantigens and the adjuvant using encapsulin
Maturation of dendritic cells and T-cells
Detection of cancer relapse using liquid biopsies of ctDNA and cancer miRNA